article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
List view / Grid view
Vaccine
article
Broad T-cell responses: designing a rhinovirus vaccine
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
article
COVID-19 in Europe – one year on from the first case
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
news
Nanoparticle vaccine shown to block range of flu strains in pre-clinical study
A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
article
Drug Target Review – Issue 1 2021
In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays.
article
SARS-CoV-2 variants: the role of sequencing and vaccine development
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
news
Spike protein analysis explains faster spread of SARS-CoV-2 variants
Using cryo-electron microscopy, researchers have imaged how the SARS-CoV-2 Spike protein changes with the D614G mutation to enable faster spread of infection.
news
Antibodies from COVID-19 vaccines less effective against SARS-CoV-2 variants
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
news
Researchers use viruses as vectors to deliver cancer vaccines
A team has used two viruses to administer specific tumour components in mice with cancer to stimulate their immune system.
news
Nanoparticle COVID-19 vaccine shows promise in pre-clinical trials
A new nanoparticle-based vaccine has demonstrated success in ferret models of COVID-19, inducing strong neutralising antibodies against SARS-CoV-2.
news
Vaccine strategy developed to fight urinary tract infections
Researchers have shown that administering a urinary tract infection vaccine directly to the bladders of mice helped them to effectively fight bacteria.
video
SARS-CoV-2 vaccines: an interview with Payton Weidenbacher
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
news
Experimental vaccine against synthetic opioids shows success in mice
A new vaccine is effective at preventing opioid overdose from fentanyl and carfentanil in rodents, according to a new study.
article
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
news
Novel DNA-based COVID-19 vaccines induce immune responses in mice
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
